Alexion, Enobia deal

Alexion will acquire bone disease company Enobia for $610 million up front and up to $470 million in milestones. Alexion will gain ENB-0040, a fusion protein of the catalytic domain of human tissue non-specific alkaline phosphatase ( TNSALP) and a bone-targeting peptide. The compound is in Phase II testing for hypophosphatasia, a rare inherited metabolic disease characterized by defective bone mineralization. ENB-0040 has Orphan Drug designation for the indication in the EU and U.S., and Fast Track designation in U.S. Alexion markets Orphan drug Soliris eculizumab to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). ...